Advocacy at a Glance STEVEN GROSSMAN 12/10/21 Advocacy at a Glance STEVEN GROSSMAN 12/10/21 Senate logjam is easing, fate of pending legislation uncertain; Califf confirmation hearing Read More Analysis and Commentary STEVEN GROSSMAN 12/3/21 Analysis and Commentary STEVEN GROSSMAN 12/3/21 Misplaced nostalgia for an appropriations process that went smoothly Read More Advocacy at a Glance STEVEN GROSSMAN 12/3/21 Advocacy at a Glance STEVEN GROSSMAN 12/3/21 New FY 22 CR extends to February 18; Medical device cybersecurity: a matter of concern. Read More Analysis and Commentary STEVEN GROSSMAN 11/19/21 Analysis and Commentary STEVEN GROSSMAN 11/19/21 Steven’s Traditional Thanksgiving Message to the FDA Stakeholder Community. Read More Advocacy at a Glance STEVEN GROSSMAN 11/19/21 Advocacy at a Glance STEVEN GROSSMAN 11/19/21 Legislative Update; Upcoming Alliance Webinar. Read More Advocacy at a Glance STEVEN GROSSMAN 11/12/21 Advocacy at a Glance STEVEN GROSSMAN 11/12/21 Legislative Update; Safer Food Supply Basics: Whole Genome Sequencing Read More Analysis and Commentary STEVEN GROSSMAN 11/12/21 Analysis and Commentary STEVEN GROSSMAN 11/12/21 Taxpayer Funding through Appropriations and User Fees: Both Important but Serve Different Purposes Read More Analysis and Commentary STEVEN GROSSMAN 11/5/21 Analysis and Commentary STEVEN GROSSMAN 11/5/21 Q&A Updates: Appropriations, Reconciliation, and ARPA-H Read More Advocacy at a Glance STEVEN GROSSMAN 11/5/21 Advocacy at a Glance STEVEN GROSSMAN 11/5/21 Sunset Rule Withdrawn; CBER’s Dr. Peter Marks Pens OP-ED on What Regulators Must Learn from COVID-19 Read More Analysis and Commentary STEVEN GROSSMAN 10/29/21 Analysis and Commentary STEVEN GROSSMAN 10/29/21 Q&A on Implications for FDA under ARPA-H Read More Advocacy at a Glance STEVEN GROSSMAN 10/29/21 Advocacy at a Glance STEVEN GROSSMAN 10/29/21 FDA May Gain $300 Million for Infrastructure from House Reconciliation Bill; Update on Status of FY 22 FDA Appropriations Read More Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Senate Labor-HHS funding Bill has several FDA references; bipartisan House Members urges USDA and FDA to cooperate on animal genetics Read More Analysis and Commentary STEVEN GROSSMAN 10/22/21 Analysis and Commentary STEVEN GROSSMAN 10/22/21 Summary of: Alliance Webinar with National Center for Toxicological Research Director Dr. Slikker, Jr. Read More Analysis and Commentary STEVEN GROSSMAN 10/15/21 Analysis and Commentary STEVEN GROSSMAN 10/15/21 More Q&As on the Status of Appropriations and the Nomination of a New FDA Commissioner Read More Advocacy at a Glance STEVEN GROSSMAN 10/15/21 Advocacy at a Glance STEVEN GROSSMAN 10/15/21 A Funding Reprieve Via CR, but Challenges Ahead;Next Steps in the Executive Branch’s Shaping of Possible ARPA-H Read More Analysis and Commentary STEVEN GROSSMAN 10/8/21 Analysis and Commentary STEVEN GROSSMAN 10/8/21 Q&As About the upcoming appointment of a new FDA Commissioner Read More Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Temporary Truce in the Budget/Debt Limit Wars; FY 22 Appropriations Bills Still Hostage. Read More Analysis and Commentary STEVEN GROSSMAN 10/1/21 Analysis and Commentary STEVEN GROSSMAN 10/1/21 Q&As on FDA Allocations: BA vs user fees; medical products vs food safety Read More Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Continuing Resolution prevent shutdown, but delays decisions; ARPA-H is a work in progress Read More Analysis and Commentary STEVEN GROSSMAN 9/24/21 Analysis and Commentary STEVEN GROSSMAN 9/24/21 Consequences of an FDA shutdown at the beginning of FY 22 Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 12/10/21 Advocacy at a Glance STEVEN GROSSMAN 12/10/21 Senate logjam is easing, fate of pending legislation uncertain; Califf confirmation hearing Read More
Analysis and Commentary STEVEN GROSSMAN 12/3/21 Analysis and Commentary STEVEN GROSSMAN 12/3/21 Misplaced nostalgia for an appropriations process that went smoothly Read More
Advocacy at a Glance STEVEN GROSSMAN 12/3/21 Advocacy at a Glance STEVEN GROSSMAN 12/3/21 New FY 22 CR extends to February 18; Medical device cybersecurity: a matter of concern. Read More
Analysis and Commentary STEVEN GROSSMAN 11/19/21 Analysis and Commentary STEVEN GROSSMAN 11/19/21 Steven’s Traditional Thanksgiving Message to the FDA Stakeholder Community. Read More
Advocacy at a Glance STEVEN GROSSMAN 11/19/21 Advocacy at a Glance STEVEN GROSSMAN 11/19/21 Legislative Update; Upcoming Alliance Webinar. Read More
Advocacy at a Glance STEVEN GROSSMAN 11/12/21 Advocacy at a Glance STEVEN GROSSMAN 11/12/21 Legislative Update; Safer Food Supply Basics: Whole Genome Sequencing Read More
Analysis and Commentary STEVEN GROSSMAN 11/12/21 Analysis and Commentary STEVEN GROSSMAN 11/12/21 Taxpayer Funding through Appropriations and User Fees: Both Important but Serve Different Purposes Read More
Analysis and Commentary STEVEN GROSSMAN 11/5/21 Analysis and Commentary STEVEN GROSSMAN 11/5/21 Q&A Updates: Appropriations, Reconciliation, and ARPA-H Read More
Advocacy at a Glance STEVEN GROSSMAN 11/5/21 Advocacy at a Glance STEVEN GROSSMAN 11/5/21 Sunset Rule Withdrawn; CBER’s Dr. Peter Marks Pens OP-ED on What Regulators Must Learn from COVID-19 Read More
Analysis and Commentary STEVEN GROSSMAN 10/29/21 Analysis and Commentary STEVEN GROSSMAN 10/29/21 Q&A on Implications for FDA under ARPA-H Read More
Advocacy at a Glance STEVEN GROSSMAN 10/29/21 Advocacy at a Glance STEVEN GROSSMAN 10/29/21 FDA May Gain $300 Million for Infrastructure from House Reconciliation Bill; Update on Status of FY 22 FDA Appropriations Read More
Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Advocacy at a Glance STEVEN GROSSMAN 10/22/21 Senate Labor-HHS funding Bill has several FDA references; bipartisan House Members urges USDA and FDA to cooperate on animal genetics Read More
Analysis and Commentary STEVEN GROSSMAN 10/22/21 Analysis and Commentary STEVEN GROSSMAN 10/22/21 Summary of: Alliance Webinar with National Center for Toxicological Research Director Dr. Slikker, Jr. Read More
Analysis and Commentary STEVEN GROSSMAN 10/15/21 Analysis and Commentary STEVEN GROSSMAN 10/15/21 More Q&As on the Status of Appropriations and the Nomination of a New FDA Commissioner Read More
Advocacy at a Glance STEVEN GROSSMAN 10/15/21 Advocacy at a Glance STEVEN GROSSMAN 10/15/21 A Funding Reprieve Via CR, but Challenges Ahead;Next Steps in the Executive Branch’s Shaping of Possible ARPA-H Read More
Analysis and Commentary STEVEN GROSSMAN 10/8/21 Analysis and Commentary STEVEN GROSSMAN 10/8/21 Q&As About the upcoming appointment of a new FDA Commissioner Read More
Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Advocacy at a Glance STEVEN GROSSMAN 10/8/21 Temporary Truce in the Budget/Debt Limit Wars; FY 22 Appropriations Bills Still Hostage. Read More
Analysis and Commentary STEVEN GROSSMAN 10/1/21 Analysis and Commentary STEVEN GROSSMAN 10/1/21 Q&As on FDA Allocations: BA vs user fees; medical products vs food safety Read More
Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Advocacy at a Glance STEVEN GROSSMAN 10/1/21 Continuing Resolution prevent shutdown, but delays decisions; ARPA-H is a work in progress Read More
Analysis and Commentary STEVEN GROSSMAN 9/24/21 Analysis and Commentary STEVEN GROSSMAN 9/24/21 Consequences of an FDA shutdown at the beginning of FY 22 Read More
